| Identification | More | [Name]
Travoprost | [CAS]
157283-68-6 | [Synonyms]
15(S)-FLU-IPR
15(S)-FLUPROSTENOL ISOPROPYL ESTER
(+/-)-16-(M-TRIFLUOROMETHYLPHENOXY)TETRANORPROSTAGLANDIN F2
(+)-9ALPHA,11ALPHA,15R-TRIHYDROXY-16-(3-(TRIFLUOROMETHYL)PHENOXY)-17,18,19,20-TETRANOR-PROSTA-5Z,13E-DIEN-1-OIC ACID, ISOPROPYL ESTER
9ALPHA,11ALPHA,15S-TRIHYDROXY-16(3-(TRIFLUOROMETHYL)PHENOXY)-17,18,19,20-TETRANOR-PROSTA-5Z,13E-DIEN-1-OIC ACID, ISOPROPYL ESTER
FLU-IPR
(+)-FLUPROSTENOL ISOPROPYL ESTER
FLUPROSTENOL ISOPROPYL ESTER
propan-2-yl (e)-7-[(1r,2s,3r,5s)-3,5-dihydroxy-2-[(e)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate
TRAVOPROST
propan-2-yl 7-[(1R,2S,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate
Propan-2-yl (E)-7-[(1R,2S,3R,5S)-3,5-dihydroxy-2-[(E)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate
(5Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-buten-1-yl]cyclopentyl]-5-heptenoic Acid 1-Methylethyl Ester
AL 6221
Travaprost
Travatan
Travoprost, (±)-16-(m-Trifluoromethylphenoxy)tetranorprostaglandin F2 | [EINECS(EC#)]
682-028-9 | [Molecular Formula]
C26H35F3O6 | [MDL Number]
MFCD03411995 | [Molecular Weight]
500.55 | [MOL File]
157283-68-6.mol |
| Chemical Properties | Back Directory | [Appearance]
Colorless Oil | [alpha ]
D20 +14.6° (c = 1.0 in methylene chloride) | [Boiling point ]
584.8±50.0 °C(Predicted) | [density ]
1.245±0.06 g/cm3(Predicted) | [Fp ]
17 °C | [storage temp. ]
−20°C
| [solubility ]
Dichloromethane (Sparingly, Sonicated), Chloroform (Sparingy), Methanol (Sparing | [form ]
ethanol solution
| [pka]
13.43±0.20(Predicted) | [color ]
Colourless to Light Beige | [Usage]
Selective FP prostaglandin receptor agonist. Isopropyl ester of (+)-fluprostenol. Antiglaucoma | [BCS Class]
2 | [Stability:]
Light Sensitive | [InChIKey]
MKPLKVHSHYCHOC-AHTXBMBWSA-N | [SMILES]
C(OC(C)C)(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 | [CAS DataBase Reference]
157283-68-6(CAS DataBase Reference) |
| Safety Data | Back Directory | [Symbol(GHS) ]
 
GHS02,GHS07 | [Signal word ]
Danger | [Hazard statements ]
H225-H319 | [Precautionary statements ]
P210-P233-P240-P241-P242-P305+P351+P338 | [Hazard Codes ]
F,Xi | [Risk Statements ]
R11:Highly Flammable.
R36/37/38:Irritating to eyes, respiratory system and skin . | [Safety Statements ]
S16:Keep away from sources of ignition-No smoking .
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S36:Wear suitable protective clothing . | [RIDADR ]
UN 1170 3/PG 2
| [WGK Germany ]
1
| [HS Code ]
2937500000 | [Storage Class]
3 - Flammable liquids | [Hazard Classifications]
Eye Irrit. 2
Flam. Liq. 2 |
| Hazard Information | Back Directory | [Description]
Travoprost was launched in the US as Travatan?, an ophthalmic solution (0.004%)
administered topically for the treatment of elevated intraocular hypertension (lOP) through
open-angle glaucoma, a common optic neuropathy and a leading cause of blindness.
Travoprost is the isopropyl ester of (+)-fluprostenol, a new prostaglandin derivative
belonging to the PGF2α, analog class. This compound can be prepared in 8 steps from a
bicyclic lactone aldehyde by a Wittig alkylidenation followed, after 2 ketonic reductions, by
a lactol opening to prostenoic acid while protecting and deprotecting appropriately.
Travoprost is a full agonist of FP receptors with a greater affinity than PGF2α, (K1 = 52 nM).
Pharmacologic studies in rabbits treated daily for a week demonstrated a significant
increase of the microvascular optic nerve head blood flow without significant alterations in
the systemic flow. In several placebo-controlled clinical studies with hundreds of patients
suffering from open-angle glaucoma or ocular hypertension, travoprost (1 to 4 pm daily)
dose-dependently reduced lOP (by about 30% at 4 pm); it was shown equal or superior to
latanoprost, another prostaglandin analog (5 pm daily) or the adrenergic ~-blocker timolol
(500 pm bid). In addition, travoprost was safe and well tolerated with a low incidence of
conjunctival hyperaemia. | [Chemical Properties]
Colorless Oil | [Originator]
Alcon (US) | [Uses]
Selective FP prostaglandin receptor agonist. Isopropyl ester of (+)-fluprostenol. Antiglaucoma | [Uses]
treatment conditions arising from excess uric acid, eg chronic gout | [Definition]
ChEBI: The isopropyl ester of prostaglandin F2alpha in which the pentyl group is replaced by a 3-(trifluoromethyl)phenoxymethyl group. A synthetic analogue of prostaglandin F2alpha, ophth
lmic solutions of travoprost are used as a topical medication for controlling the progression of open-angle glaucoma and ocular hypertension, by reducing intraocular pressure. It is a pro-drug; the isopropyl ester group is hydrolysed by esterases in the co
nea to the biologically active free acid, fluprostenol. | [Brand name]
Travatan | [General Description]
Travoprost (Travatan and Travatan-Z) is supplied asa 2.5- or 5.0-mL sterile 0.004% ophthalmic solution in a4.0- or 7.5-mL size container. Travoprost is claimed to bethe most potent and FP-specific analog in this product category. Cautions and side effects are similar to those givenpreviously. |
|
| Company Name: |
shang hai langyang Gold
|
| Telephone: |
15900804645 |
| Website: |
www.shlangyoung.com/index.htm |
| Company Name: |
J & K SCIENTIFIC LTD.
|
| Telephone: |
18210857532 18210857532 |
| Website: |
https://www.jkchemical.com |
|